X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs JUBILANT LIFE SCIENCES - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD JUBILANT LIFE SCIENCES STRIDES SHASUN LTD/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 44.0 17.1 257.9% View Chart
P/BV x 1.1 4.5 24.4% View Chart
Dividend Yield % 0.9 0.4 223.5%  

Financials

 STRIDES SHASUN LTD   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
JUBILANT LIFE SCIENCES
Mar-14
STRIDES SHASUN LTD/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,275187 682.4%   
Low Rs91865 1,410.1%   
Sales per share (Unadj.) Rs389.6364.3 106.9%  
Earnings per share (Unadj.) Rs28.06.8 408.5%  
Cash flow per share (Unadj.) Rs48.924.5 199.6%  
Dividends per share (Unadj.) Rs4.503.00 150.0%  
Dividend yield (eoy) %0.42.4 17.2%  
Book value per share (Unadj.) Rs303.1164.9 183.8%  
Shares outstanding (eoy) m89.42159.28 56.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.3 814.1%   
Avg P/E ratio x39.218.4 213.1%  
P/CF ratio (eoy) x22.45.1 436.1%  
Price / Book Value ratio x3.60.8 473.5%  
Dividend payout %16.143.8 36.7%   
Avg Mkt Cap Rs m98,03620,061 488.7%   
No. of employees `0005.86.2 93.8%   
Total wages/salary Rs m5,88111,052 53.2%   
Avg. sales/employee Rs Th6,005.99,383.0 64.0%   
Avg. wages/employee Rs Th1,014.01,786.9 56.7%   
Avg. net profit/employee Rs Th431.2176.3 244.6%   
INCOME DATA
Net Sales Rs m34,83458,034 60.0%  
Other income Rs m1,686191 884.5%   
Total revenues Rs m36,52058,224 62.7%   
Gross profit Rs m6,4285,786 111.1%  
Depreciation Rs m1,8722,812 66.6%   
Interest Rs m2,2693,237 70.1%   
Profit before tax Rs m3,973-72 -5,510.4%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0062,145 -46.9%   
Tax Rs m470696 67.5%   
Profit after tax Rs m2,5011,090 229.4%  
Gross profit margin %18.510.0 185.1%  
Effective tax rate %11.8-965.9 -1.2%   
Net profit margin %7.21.9 382.1%  
BALANCE SHEET DATA
Current assets Rs m38,16529,280 130.3%   
Current liabilities Rs m30,40238,912 78.1%   
Net working cap to sales %22.3-16.6 -134.3%  
Current ratio x1.30.8 166.8%  
Inventory Days Days7784 91.7%  
Debtors Days Days10451 206.1%  
Net fixed assets Rs m37,63955,712 67.6%   
Share capital Rs m894155 578.8%   
"Free" reserves Rs m26,21020,968 125.0%   
Net worth Rs m27,10526,265 103.2%   
Long term debt Rs m16,37717,169 95.4%   
Total assets Rs m81,16888,606 91.6%  
Interest coverage x2.81.0 281.3%   
Debt to equity ratio x0.60.7 92.4%  
Sales to assets ratio x0.40.7 65.5%   
Return on assets %5.94.9 120.3%  
Return on equity %9.24.2 222.3%  
Return on capital %12.111.6 104.2%  
Exports to sales %037.8 0.0%   
Imports to sales %016.5 0.0%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs mNA9,567 0.0%   
Fx inflow Rs m13,46522,004 61.2%   
Fx outflow Rs m4,07611,749 34.7%   
Net fx Rs m9,38910,255 91.6%   
CASH FLOW
From Operations Rs m2,8818,026 35.9%  
From Investments Rs m-7,051-1,744 404.3%  
From Financial Activity Rs m3,382-4,447 -76.0%  
Net Cashflow Rs m-7881,834 -42.9%  

Share Holding

Indian Promoters % 27.7 45.6 60.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 37.8 8.7 434.5%  
FIIs % 8.6 21.2 40.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 21.1 122.7%  
Shareholders   56,241 23,815 236.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - DISHMAN PHARMA COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS